Are EMSCULPT NEO and EMSELLA Safe?

Muscle contractions, warmth and individual tolerance are reviewed during treatment. Report pain, excessive heat or unexpected discomfort promptly so the clinician can adjust, pause or stop the session.

Is treatment painful? · Who May Not Be Suitable for EMSCULPT NEO or EMSELLA?

For appropriately selected patients, EMSCULPT NEO and EMSELLA are non-invasive treatments that have generally been well tolerated in published clinical studies. However, neither treatment is risk-free and neither is appropriate for everyone.

The most important part of the answer is therefore not simply whether the machines are "safe".

It is:

Are they safe and appropriate for this particular patient?

That depends on the treatment, medical history, implanted devices, treatment area and other individual factors.

This is why ¹EM assesses suitability before treatment begins.

Neither treatment requires a surgical incision.

EMSCULPT NEO combines:

The electromagnetic component produces powerful involuntary muscular contractions. The radiofrequency component heats tissue in the treatment area.

EMSELLA uses high-intensity focused electromagnetic energy to stimulate repeated contractions of the pelvic floor muscles while the patient remains seated and clothed.

Neither procedure involves surgery or an injectable treatment.

Non-invasive, however, does not mean medically irrelevant.

Both technologies expose tissues to energy capable of producing biological effects, which is why contraindications and appropriate patient selection matter.

A sham-controlled trial involving 72 patients assessed simultaneous radiofrequency and high-intensity focused electromagnetic treatment of the abdomen. Treatments were reported as comfortable and the active treatment group reported high satisfaction.

A smaller study assessing multiple same-day radiofrequency plus HIFEM treatments found no adverse events and no clinically significant changes in the measured liver-function or lipid parameters, although only 10 people participated, so it should not be interpreted as definitive evidence of safety for every patient or protocol.

The overall published evidence base remains relatively modest.

A 2025 critical review of EMSCULPT NEO studies also highlighted limitations in the literature, including potential conflicts of interest and methodological issues. It noted few reported adverse events but questioned how confidently some efficacy results could be interpreted.

At ¹EM, we think those limitations are worth stating openly.

Published EMSELLA studies have generally reported good short-term tolerability in appropriately screened patients.

One study of 75 women receiving six HIFEM pelvic-floor sessions reported no pain, downtime or adverse events.

A more recent 2025 systematic review and meta-analysis assessed seven studies of HIFEM for urinary incontinence. Most included studies did not highlight significant safety issues, although the authors cautioned that the literature was heterogeneous and potentially affected by bias and called for stronger trials.

A 2025 study of HIFEM following prostatectomy involving 27 men also reported no adverse events during the short follow-up period.

These findings are encouraging.

They do not mean that EMSELLA is suitable for everybody or that complications are impossible.

FDA guidance for magnetic-field body treatments lists potential effects including:

This is not particularly surprising given that the technology intentionally produces repeated muscular contractions.

Some people describe treatment as intense, particularly as the energy level increases.

Treatment intensity should therefore be adjusted appropriately rather than assuming that maximum intensity is always necessary or desirable for every patient.

Radiofrequency energy produces heating.

FDA guidance for RF body-contouring technologies identifies potential complications including:

The existence of a potential complication does not mean it is expected to occur.

It means treatment should be delivered appropriately, contraindications should be respected, and patients should be able to report unexpected discomfort during treatment.

Because electromagnetic fields can interact with active implanted electronic devices.

FDA guidance specifically advises against magnetic-field body treatment in people with active implants such as pacemakers or implantable cardioverter defibrillators. The FDA has also documented the broader principle that strong magnets can alter the behaviour of some implanted cardiac devices.

At ¹EM, a patient with a pacemaker would therefore not simply be treated because they otherwise appear healthy.

Both electromagnetic fields and, for EMSCULPT NEO, radiofrequency energy create safety considerations around implanted metal.

FDA guidance advises against use of magnetic-field body-treatment devices in people with metal beneath the skin and similarly identifies metal implants as a contraindication for RF body-contouring devices.

However, patients often do not know exactly what material their implant contains or how its location relates to the proposed treatment field.

Final treatment suitability is a clinical decision.

Where relevant, Dr Emir can establish exactly:

If the implant falls within a contraindication, treatment does not proceed.

We do not perform EMSCULPT NEO or EMSELLA during pregnancy.

Pregnancy has been excluded from HIFEM clinical research, including published EMSELLA studies.

Elective treatment can be reconsidered after pregnancy when medically appropriate.

This requires a nuanced answer.

Both HIFEM and related electromagnetic muscle-stimulation technologies have now been studied across multiple applications and patient groups, but the evidence base is considerably smaller than that available for many longstanding medical interventions.

For EMSELLA specifically, a 2025 systematic review concluded that existing studies suggest HIFEM may be a safe and effective non-invasive treatment for female urinary incontinence, while emphasising the need for better-quality trials because of heterogeneity and possible bias.

For EMSCULPT NEO, controlled clinical research exists, but critics have raised valid questions about study methodology and manufacturer relationships within parts of the published literature.

So the appropriate statement is not:

"There are zero risks and the science is settled."

Nor is it:

"The treatments are experimental and unsafe."

The more accurate answer is that published evidence has generally shown good tolerability in appropriately selected participants, while important contraindications and limitations remain.

No.

Regulatory authorisation of a medical device does not mean every patient can safely use it.

The FDA explicitly states that aesthetic medical devices can carry risks and that patients should discuss benefits, limitations and personal risk factors with their healthcare provider.

The same principle applies regardless of how heavily a device is marketed as non-invasive.

¹EM does not treat safety as a checkbox immediately before turning the machine on.

The process begins with understanding the patient.

Depending on the treatment and presentation, this can include:

We identify relevant medical conditions, medications, previous procedures and treatment goals.

Pacemakers, defibrillators, neurostimulators, drug pumps, metal implants, joint replacements, intrauterine devices and other implanted devices need to be disclosed.

The treatment area matters, particularly where previous surgery, implants, altered sensation or active tissue problems are involved.

Straightforward questions can be handled by the clinical team.

Complex medical or implant-related questions can be escalated to Dr Emir.

The fact that a treatment exists does not mean it is the right answer.

Sometimes the safest and most appropriate recommendation is not to treat.

If something changes medically during a treatment program, the team should know.

Suitability is not frozen permanently on the date of the first consultation.

Because non-surgical and risk-free are not synonyms.

The FDA describes non-invasive body contouring as a medical procedure with benefits, risks and limitations and specifically recommends discussing implanted devices, medications, surgery, pregnancy and relevant medical conditions with the treating healthcare provider.

A good safety system therefore tries to identify problems before treatment rather than relying on the fact that serious complications are uncommon.

That question is too broad to answer with a simple yes.

EMSCULPT NEO avoids many things inherently associated with surgery, including incisions and surgical anaesthesia.

But it is also used for different purposes and produces a different magnitude and type of treatment effect.

The right comparison is therefore usually based on:

Read: Is EMSCULPT NEO better than liposuction?

Men have been treated with pelvic-floor HIFEM in published clinical research, including patients experiencing urinary incontinence following prostate surgery.

A 2025 study involving 27 men with post-prostatectomy incontinence reported no adverse events during treatment or the short follow-up period, although larger and longer-term research is still needed.

Individual suitability still needs to be assessed.

Learn about men's pelvic health at ¹EM

It may be appropriate for selected patients, but the words "after surgery" matter.

The treatment should not be commenced simply because a patient has urinary leakage following a prostate procedure.

Timing, surgical recovery, current symptoms and medical context should be assessed first.

Published research has evaluated HIFEM in men with persistent post-prostatectomy urinary incontinence, but that is not equivalent to saying treatment should begin immediately after an operation.

No.

Relevant medical information needs to be disclosed before treatment.

That includes information you may think is unrelated, particularly:

If you are unsure whether something matters, mention it.

Tell the treating team immediately.

Unexpected pain, excessive heat, unusual sensations or any other concern should not simply be endured because treatment is "supposed to feel intense".

The treatment can be stopped and reassessed.

For appropriately screened patients, published studies have generally found the treatment well tolerated. It still has contraindications and potential adverse effects, particularly because it uses both electromagnetic and radiofrequency energy.

Published studies and a recent systematic review have generally reported good short-term tolerability in appropriately selected patients. The evidence base continues to develop.

Potential effects include muscular soreness or cramping. Radiofrequency treatment also carries risks associated with heating, including discomfort and, less commonly, thermal injury.

The electromagnetic stimulation can produce strong muscle contractions, and muscle soreness or cramping can occur with magnetic-field muscle stimulation.

No. Active implanted cardiac devices such as pacemakers are contraindications to magnetic-field body treatments.

Tell us before treatment. Implant-specific suitability cannot safely be determined by An online answer or reception alone.

No.

Not always.

Some conditions are contraindications. Others require additional assessment.

If you are unsure, disclose the condition and allow the clinical team to determine the appropriate next step.

No medical or aesthetic treatment should be represented as having zero risk.

The goal is to select the right patient, use the treatment appropriately, recognise contraindications and make sure the likely benefit justifies proceeding.

You do not need to decide that from an online contraindication list.

Tell us about your medical history, implants, previous procedures and what you are hoping to achieve.

If your situation requires individual clinical judgement, it can be reviewed by Dr Emir before treatment is considered.

Internal links:

Explore EMSCULPT NEO

Explore EMSELLA

Explore Men's Pelvic Health

1. US Food and Drug Administration. Non-Invasive Body Contouring Technologies. Covers recognised risks, patient screening, radiofrequency and magnetic-field contraindications.

2. Samuels JB, Katz B, Weiss RA. Radiofrequency Heating and High-Intensity Focused Electromagnetic Treatment Delivered Simultaneously: The First Sham-Controlled Randomized Trial. Plastic and Reconstructive Surgery. 2022.

3. Leonardo K, Rahardjo HE, Afriansyah A. Noninvasive High-Intensity Focused Electromagnetic Therapy in Women With Urinary Incontinence: A Systematic Review and Meta-Analysis. Neurourology and Urodynamics. 2025.

4. Samuels JB, et al. Safety and Efficacy of a Non-Invasive High-Intensity Focused Electromagnetic Field Device for Treatment of Urinary Incontinence and Enhancement of Quality of Life. Lasers in Surgery and Medicine.

5. Swanson E. Body Contouring With Electromagnetic Treatment Plus Radiofrequency: A Review. Annals of Plastic Surgery. 2025. Provides a critical appraisal of the EMSCULPT NEO evidence base and potential study limitations.

This article provides general information and cannot determine individual treatment suitability. Implanted devices, pregnancy, medical conditions, medications and previous procedures should be disclosed before treatment. Applicable manufacturer and medical-device safety requirements take precedence over general information online.